Treatment outcome
| Patient . | Treatment of LCH lesions . | Treatment of ECD lesions . | |||||
|---|---|---|---|---|---|---|---|
| No. of lines . | Follow-up during treatment (mo) . | Efficacy: LCH/ECD . | Type of IFN-α . | Dose of IFN-α . | Follow-up during treatment (mo) . | Efficacy: LCH/ECD . | |
| 1 | 0 | — | −/– | PEG | 135 µg/w | <1 | –/– |
| 2 | 1 | 13 | Partial/partial | Standard | 27 MIU/w | 12 | Partial/partial |
| 3 | 0 | — | –/– | PEG | 135 µg/w | 24 | Yes/partial |
| 4 | 1 | 15 | No/no | Standard | 13.5 MIU/w | 13 | Yes/partial |
| 5 | 0 | — | –/– | PEG | 135 µg/w | 18 | Partial/partial |
| 6 | 1 | 3 | No/no | — | — | — | –/– |
| 7 | 1 | 4 | –/– | PEG | 135 µg/w | 16 | No/no |
| 8 | 0 | — | –/– | PEG | 180 µg/w | 7 | –/No |
| 9 | 0 | — | –/– | — | — | — | –/– |
| 10 | 1 | 1 | No/no | Standard | 18 MIU/w | 34 | No/no |
| 11 | 3 | 43 | Partial/– | Standard | 9 MIU/w | 19 | No/no |
| 12 | 3 | 153 | Partial/no | Standard | 27 MIU/w | 39 | –/Partial |
| 13 | ND | 144 | Yes/– | — | — | — | –/– |
| 14 | 3 | 54 | No/– | Standard | 27 MIU/w | 18 | –/No |
| 15 | 4 | 138 | Partial/– | — | — | — | –/– |
| 16 | 3 | 270 | Yes/– | Standard | 27 MIU/w | 51 | –/Partial |
| 17 | 1 | 370 | Yes/– | PEG | 180 µg/w | 30 | –/No |
| 18 | 4 | 18 | No/– | Standard | 18 MIU/w | 10 | No/no |
| 19 | 2 | 300 | No/– | Standard | 13.5 MIU/w | <1 | –/– |
| 20 | 3 | 72 | Yes/– | Standard | 13.5 MIU/w | 6 | –/Yes |
| 21 | 3 | 177 | No/– | PEG | 135 µg/w | 29 | –/Yes |
| 22 | 1 | 40 | No/– | PEG | 135 µg/w | <1 | –/– |
| 23 | 2 | 36 | No/– | PEG | 135 µg/w | 28 | No/no |
| Patient . | Treatment of LCH lesions . | Treatment of ECD lesions . | |||||
|---|---|---|---|---|---|---|---|
| No. of lines . | Follow-up during treatment (mo) . | Efficacy: LCH/ECD . | Type of IFN-α . | Dose of IFN-α . | Follow-up during treatment (mo) . | Efficacy: LCH/ECD . | |
| 1 | 0 | — | −/– | PEG | 135 µg/w | <1 | –/– |
| 2 | 1 | 13 | Partial/partial | Standard | 27 MIU/w | 12 | Partial/partial |
| 3 | 0 | — | –/– | PEG | 135 µg/w | 24 | Yes/partial |
| 4 | 1 | 15 | No/no | Standard | 13.5 MIU/w | 13 | Yes/partial |
| 5 | 0 | — | –/– | PEG | 135 µg/w | 18 | Partial/partial |
| 6 | 1 | 3 | No/no | — | — | — | –/– |
| 7 | 1 | 4 | –/– | PEG | 135 µg/w | 16 | No/no |
| 8 | 0 | — | –/– | PEG | 180 µg/w | 7 | –/No |
| 9 | 0 | — | –/– | — | — | — | –/– |
| 10 | 1 | 1 | No/no | Standard | 18 MIU/w | 34 | No/no |
| 11 | 3 | 43 | Partial/– | Standard | 9 MIU/w | 19 | No/no |
| 12 | 3 | 153 | Partial/no | Standard | 27 MIU/w | 39 | –/Partial |
| 13 | ND | 144 | Yes/– | — | — | — | –/– |
| 14 | 3 | 54 | No/– | Standard | 27 MIU/w | 18 | –/No |
| 15 | 4 | 138 | Partial/– | — | — | — | –/– |
| 16 | 3 | 270 | Yes/– | Standard | 27 MIU/w | 51 | –/Partial |
| 17 | 1 | 370 | Yes/– | PEG | 180 µg/w | 30 | –/No |
| 18 | 4 | 18 | No/– | Standard | 18 MIU/w | 10 | No/no |
| 19 | 2 | 300 | No/– | Standard | 13.5 MIU/w | <1 | –/– |
| 20 | 3 | 72 | Yes/– | Standard | 13.5 MIU/w | 6 | –/Yes |
| 21 | 3 | 177 | No/– | PEG | 135 µg/w | 29 | –/Yes |
| 22 | 1 | 40 | No/– | PEG | 135 µg/w | <1 | –/– |
| 23 | 2 | 36 | No/– | PEG | 135 µg/w | 28 | No/no |
(–), not assessable; PEG, pegylated interferon-α2a.